A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients With Non-malignant Chronic Pain Receiving Opioid Therapy

Trial Profile

A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients With Non-malignant Chronic Pain Receiving Opioid Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Dolcanatide (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 16 Mar 2015 Status changed from active, no longer recruiting to completed according to Synergy Pharmaceuticals' media release.
    • 17 Jul 2014 Status changed from recruiting to active, no longer recruiting according to a Synergy Pharmaceuticals media release.
    • 13 May 2014 Planned End Date changed from 1 May 2014 to 1 Nov 2014 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top